nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—SLC6A4—chronic obstructive pulmonary disease	0.218	0.565	CbGaD
Paroxetine—HTR2A—chronic obstructive pulmonary disease	0.168	0.435	CbGaD
Paroxetine—CHRM5—Tiotropium—chronic obstructive pulmonary disease	0.0877	0.228	CbGbCtD
Paroxetine—CHRM3—Tiotropium—chronic obstructive pulmonary disease	0.0561	0.146	CbGbCtD
Paroxetine—CHRM1—Tiotropium—chronic obstructive pulmonary disease	0.0488	0.127	CbGbCtD
Paroxetine—CHRM2—Tiotropium—chronic obstructive pulmonary disease	0.045	0.117	CbGbCtD
Paroxetine—CYP2C8—Montelukast—chronic obstructive pulmonary disease	0.0219	0.0568	CbGbCtD
Paroxetine—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0201	0.0523	CbGbCtD
Paroxetine—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0201	0.0523	CbGbCtD
Paroxetine—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0184	0.0478	CbGbCtD
Paroxetine—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0184	0.0478	CbGbCtD
Paroxetine—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0164	0.0426	CbGbCtD
Paroxetine—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0152	0.0396	CbGbCtD
Paroxetine—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.00868	0.0226	CbGbCtD
Paroxetine—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.0082	0.0213	CbGbCtD
Paroxetine—HTR2A—phrenic nerve—chronic obstructive pulmonary disease	0.00652	0.277	CbGeAlD
Paroxetine—HTR2A—pulmonary artery—chronic obstructive pulmonary disease	0.00237	0.1	CbGeAlD
Paroxetine—TACR1—respiratory system—chronic obstructive pulmonary disease	0.00163	0.0692	CbGeAlD
Paroxetine—TACR1—connective tissue—chronic obstructive pulmonary disease	0.00144	0.061	CbGeAlD
Paroxetine—TACR1—smooth muscle tissue—chronic obstructive pulmonary disease	0.00131	0.0558	CbGeAlD
Paroxetine—TACR1—trachea—chronic obstructive pulmonary disease	0.00121	0.0512	CbGeAlD
Paroxetine—TACR1—lung—chronic obstructive pulmonary disease	0.000866	0.0368	CbGeAlD
Paroxetine—SLC6A3—respiratory system—chronic obstructive pulmonary disease	0.000821	0.0348	CbGeAlD
Paroxetine—SLC6A4—respiratory system—chronic obstructive pulmonary disease	0.000752	0.0319	CbGeAlD
Paroxetine—SLC6A2—respiratory system—chronic obstructive pulmonary disease	0.000662	0.0281	CbGeAlD
Paroxetine—CHRM1—trachea—chronic obstructive pulmonary disease	0.000554	0.0235	CbGeAlD
Paroxetine—CHRM3—smooth muscle tissue—chronic obstructive pulmonary disease	0.00054	0.0229	CbGeAlD
Paroxetine—CYP2B6—respiratory system—chronic obstructive pulmonary disease	0.000488	0.0207	CbGeAlD
Paroxetine—SLC6A3—lung—chronic obstructive pulmonary disease	0.000436	0.0185	CbGeAlD
Paroxetine—CYP2B6—bronchus—chronic obstructive pulmonary disease	0.000402	0.017	CbGeAlD
Paroxetine—SLC6A4—lung—chronic obstructive pulmonary disease	0.000399	0.0169	CbGeAlD
Paroxetine—HTR2A—respiratory system—chronic obstructive pulmonary disease	0.000398	0.0169	CbGeAlD
Paroxetine—CHRM1—lung—chronic obstructive pulmonary disease	0.000398	0.0169	CbGeAlD
Paroxetine—SLC6A2—lung—chronic obstructive pulmonary disease	0.000352	0.0149	CbGeAlD
Paroxetine—HTR2A—connective tissue—chronic obstructive pulmonary disease	0.00035	0.0149	CbGeAlD
Paroxetine—HTR2A—smooth muscle tissue—chronic obstructive pulmonary disease	0.00032	0.0136	CbGeAlD
Paroxetine—HTR2A—trachea—chronic obstructive pulmonary disease	0.000294	0.0125	CbGeAlD
Paroxetine—ABCB1—respiratory system—chronic obstructive pulmonary disease	0.000261	0.0111	CbGeAlD
Paroxetine—CYP2B6—lung—chronic obstructive pulmonary disease	0.000259	0.011	CbGeAlD
Paroxetine—HTR2A—lung—chronic obstructive pulmonary disease	0.000211	0.00897	CbGeAlD
Paroxetine—ABCB1—trachea—chronic obstructive pulmonary disease	0.000193	0.00818	CbGeAlD
Paroxetine—ABCB1—lung—chronic obstructive pulmonary disease	0.000138	0.00588	CbGeAlD
Paroxetine—Oedema—Salbutamol—chronic obstructive pulmonary disease	7.91e-05	0.000481	CcSEcCtD
Paroxetine—Infection—Salbutamol—chronic obstructive pulmonary disease	7.85e-05	0.000478	CcSEcCtD
Paroxetine—Hypotension—Formoterol—chronic obstructive pulmonary disease	7.82e-05	0.000476	CcSEcCtD
Paroxetine—Hypotension—Arformoterol—chronic obstructive pulmonary disease	7.82e-05	0.000476	CcSEcCtD
Paroxetine—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	7.82e-05	0.000476	CcSEcCtD
Paroxetine—Pruritus—Aminophylline—chronic obstructive pulmonary disease	7.78e-05	0.000474	CcSEcCtD
Paroxetine—Shock—Salbutamol—chronic obstructive pulmonary disease	7.78e-05	0.000473	CcSEcCtD
Paroxetine—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	7.77e-05	0.000473	CcSEcCtD
Paroxetine—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	7.75e-05	0.000472	CcSEcCtD
Paroxetine—Thrombophlebitis—Prednisone—chronic obstructive pulmonary disease	7.74e-05	0.000471	CcSEcCtD
Paroxetine—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	7.72e-05	0.000469	CcSEcCtD
Paroxetine—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	7.71e-05	0.000469	CcSEcCtD
Paroxetine—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	7.68e-05	0.000467	CcSEcCtD
Paroxetine—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	7.64e-05	0.000465	CcSEcCtD
Paroxetine—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	7.64e-05	0.000465	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	7.63e-05	0.000464	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	7.63e-05	0.000464	CcSEcCtD
Paroxetine—Insomnia—Arformoterol—chronic obstructive pulmonary disease	7.57e-05	0.000461	CcSEcCtD
Paroxetine—Insomnia—Formoterol—chronic obstructive pulmonary disease	7.57e-05	0.000461	CcSEcCtD
Paroxetine—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	7.53e-05	0.000458	CcSEcCtD
Paroxetine—Vascular purpura—Prednisone—chronic obstructive pulmonary disease	7.49e-05	0.000456	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	7.47e-05	0.000455	CcSEcCtD
Paroxetine—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	7.46e-05	0.000454	CcSEcCtD
Paroxetine—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	7.46e-05	0.000454	CcSEcCtD
Paroxetine—Somnolence—Arformoterol—chronic obstructive pulmonary disease	7.44e-05	0.000453	CcSEcCtD
Paroxetine—Somnolence—Formoterol—chronic obstructive pulmonary disease	7.44e-05	0.000453	CcSEcCtD
Paroxetine—Insomnia—Montelukast—chronic obstructive pulmonary disease	7.42e-05	0.000451	CcSEcCtD
Paroxetine—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	7.39e-05	0.00045	CcSEcCtD
Paroxetine—Hypotension—Salbutamol—chronic obstructive pulmonary disease	7.39e-05	0.00045	CcSEcCtD
Paroxetine—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	7.37e-05	0.000448	CcSEcCtD
Paroxetine—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	7.37e-05	0.000448	CcSEcCtD
Paroxetine—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	7.36e-05	0.000448	CcSEcCtD
Paroxetine—Pruritus—Tiotropium—chronic obstructive pulmonary disease	7.34e-05	0.000447	CcSEcCtD
Paroxetine—Injury—Prednisone—chronic obstructive pulmonary disease	7.29e-05	0.000444	CcSEcCtD
Paroxetine—Somnolence—Montelukast—chronic obstructive pulmonary disease	7.29e-05	0.000444	CcSEcCtD
Paroxetine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	7.27e-05	0.000443	CcSEcCtD
Paroxetine—Weight increased—Prednisolone—chronic obstructive pulmonary disease	7.26e-05	0.000442	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	7.23e-05	0.00044	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	7.23e-05	0.00044	CcSEcCtD
Paroxetine—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	7.22e-05	0.000439	CcSEcCtD
Paroxetine—Fatigue—Arformoterol—chronic obstructive pulmonary disease	7.22e-05	0.000439	CcSEcCtD
Paroxetine—Fatigue—Formoterol—chronic obstructive pulmonary disease	7.22e-05	0.000439	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	7.2e-05	0.000438	CcSEcCtD
Paroxetine—Constipation—Arformoterol—chronic obstructive pulmonary disease	7.16e-05	0.000436	CcSEcCtD
Paroxetine—Pain—Arformoterol—chronic obstructive pulmonary disease	7.16e-05	0.000436	CcSEcCtD
Paroxetine—Pain—Formoterol—chronic obstructive pulmonary disease	7.16e-05	0.000436	CcSEcCtD
Paroxetine—Constipation—Formoterol—chronic obstructive pulmonary disease	7.16e-05	0.000436	CcSEcCtD
Paroxetine—Insomnia—Salbutamol—chronic obstructive pulmonary disease	7.15e-05	0.000435	CcSEcCtD
Paroxetine—Amnesia—Prednisone—chronic obstructive pulmonary disease	7.14e-05	0.000434	CcSEcCtD
Paroxetine—Increased appetite—Prednisone—chronic obstructive pulmonary disease	7.14e-05	0.000434	CcSEcCtD
Paroxetine—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	7.1e-05	0.000432	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	7.08e-05	0.000431	CcSEcCtD
Paroxetine—Fatigue—Montelukast—chronic obstructive pulmonary disease	7.07e-05	0.00043	CcSEcCtD
Paroxetine—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	7.05e-05	0.000429	CcSEcCtD
Paroxetine—Somnolence—Salbutamol—chronic obstructive pulmonary disease	7.03e-05	0.000428	CcSEcCtD
Paroxetine—Pain—Montelukast—chronic obstructive pulmonary disease	7.01e-05	0.000427	CcSEcCtD
Paroxetine—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	7.01e-05	0.000426	CcSEcCtD
Paroxetine—Vomiting—Aminophylline—chronic obstructive pulmonary disease	6.99e-05	0.000426	CcSEcCtD
Paroxetine—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	6.97e-05	0.000424	CcSEcCtD
Paroxetine—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	6.97e-05	0.000424	CcSEcCtD
Paroxetine—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	6.96e-05	0.000423	CcSEcCtD
Paroxetine—Purpura—Prednisone—chronic obstructive pulmonary disease	6.96e-05	0.000423	CcSEcCtD
Paroxetine—Rash—Aminophylline—chronic obstructive pulmonary disease	6.94e-05	0.000422	CcSEcCtD
Paroxetine—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	6.93e-05	0.000422	CcSEcCtD
Paroxetine—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	6.91e-05	0.000421	CcSEcCtD
Paroxetine—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	6.9e-05	0.00042	CcSEcCtD
Paroxetine—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	6.9e-05	0.00042	CcSEcCtD
Paroxetine—Headache—Aminophylline—chronic obstructive pulmonary disease	6.89e-05	0.000419	CcSEcCtD
Paroxetine—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	6.87e-05	0.000418	CcSEcCtD
Paroxetine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	6.86e-05	0.000417	CcSEcCtD
Paroxetine—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	6.85e-05	0.000417	CcSEcCtD
Paroxetine—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	6.85e-05	0.000417	CcSEcCtD
Paroxetine—Lethargy—Prednisone—chronic obstructive pulmonary disease	6.84e-05	0.000416	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	6.83e-05	0.000415	CcSEcCtD
Paroxetine—Fatigue—Salbutamol—chronic obstructive pulmonary disease	6.82e-05	0.000415	CcSEcCtD
Paroxetine—Pain—Salbutamol—chronic obstructive pulmonary disease	6.76e-05	0.000411	CcSEcCtD
Paroxetine—Constipation—Salbutamol—chronic obstructive pulmonary disease	6.76e-05	0.000411	CcSEcCtD
Paroxetine—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	6.71e-05	0.000408	CcSEcCtD
Paroxetine—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	6.7e-05	0.000408	CcSEcCtD
Paroxetine—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	6.7e-05	0.000408	CcSEcCtD
Paroxetine—Urticaria—Formoterol—chronic obstructive pulmonary disease	6.65e-05	0.000405	CcSEcCtD
Paroxetine—Urticaria—Arformoterol—chronic obstructive pulmonary disease	6.65e-05	0.000405	CcSEcCtD
Paroxetine—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	6.62e-05	0.000403	CcSEcCtD
Paroxetine—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	6.62e-05	0.000403	CcSEcCtD
Paroxetine—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	6.62e-05	0.000403	CcSEcCtD
Paroxetine—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	6.62e-05	0.000403	CcSEcCtD
Paroxetine—Affect lability—Prednisone—chronic obstructive pulmonary disease	6.6e-05	0.000402	CcSEcCtD
Paroxetine—Vomiting—Tiotropium—chronic obstructive pulmonary disease	6.6e-05	0.000401	CcSEcCtD
Paroxetine—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	6.55e-05	0.000398	CcSEcCtD
Paroxetine—Rash—Tiotropium—chronic obstructive pulmonary disease	6.54e-05	0.000398	CcSEcCtD
Paroxetine—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	6.54e-05	0.000398	CcSEcCtD
Paroxetine—Nausea—Aminophylline—chronic obstructive pulmonary disease	6.53e-05	0.000398	CcSEcCtD
Paroxetine—Urticaria—Montelukast—chronic obstructive pulmonary disease	6.51e-05	0.000396	CcSEcCtD
Paroxetine—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	6.51e-05	0.000396	CcSEcCtD
Paroxetine—Headache—Tiotropium—chronic obstructive pulmonary disease	6.5e-05	0.000395	CcSEcCtD
Paroxetine—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	6.5e-05	0.000395	CcSEcCtD
Paroxetine—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	6.48e-05	0.000394	CcSEcCtD
Paroxetine—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	6.48e-05	0.000394	CcSEcCtD
Paroxetine—Face oedema—Prednisone—chronic obstructive pulmonary disease	6.47e-05	0.000394	CcSEcCtD
Paroxetine—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	6.46e-05	0.000393	CcSEcCtD
Paroxetine—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	6.41e-05	0.00039	CcSEcCtD
Paroxetine—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	6.38e-05	0.000388	CcSEcCtD
Paroxetine—Mood swings—Prednisone—chronic obstructive pulmonary disease	6.35e-05	0.000386	CcSEcCtD
Paroxetine—Urticaria—Salbutamol—chronic obstructive pulmonary disease	6.28e-05	0.000382	CcSEcCtD
Paroxetine—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	6.25e-05	0.00038	CcSEcCtD
Paroxetine—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	6.25e-05	0.00038	CcSEcCtD
Paroxetine—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	6.17e-05	0.000375	CcSEcCtD
Paroxetine—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	6.17e-05	0.000375	CcSEcCtD
Paroxetine—Nausea—Tiotropium—chronic obstructive pulmonary disease	6.16e-05	0.000375	CcSEcCtD
Paroxetine—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	6.15e-05	0.000374	CcSEcCtD
Paroxetine—Dry skin—Prednisone—chronic obstructive pulmonary disease	6.14e-05	0.000374	CcSEcCtD
Paroxetine—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	6.1e-05	0.000371	CcSEcCtD
Paroxetine—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	6.04e-05	0.000368	CcSEcCtD
Paroxetine—Asthenia—Formoterol—chronic obstructive pulmonary disease	6.01e-05	0.000366	CcSEcCtD
Paroxetine—Asthenia—Arformoterol—chronic obstructive pulmonary disease	6.01e-05	0.000366	CcSEcCtD
Paroxetine—Pruritus—Formoterol—chronic obstructive pulmonary disease	5.92e-05	0.00036	CcSEcCtD
Paroxetine—Pruritus—Arformoterol—chronic obstructive pulmonary disease	5.92e-05	0.00036	CcSEcCtD
Paroxetine—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	5.91e-05	0.00036	CcSEcCtD
Paroxetine—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	5.91e-05	0.00036	CcSEcCtD
Paroxetine—Asthenia—Montelukast—chronic obstructive pulmonary disease	5.88e-05	0.000358	CcSEcCtD
Paroxetine—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	5.82e-05	0.000354	CcSEcCtD
Paroxetine—Pruritus—Montelukast—chronic obstructive pulmonary disease	5.8e-05	0.000353	CcSEcCtD
Paroxetine—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	5.73e-05	0.000349	CcSEcCtD
Paroxetine—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	5.73e-05	0.000349	CcSEcCtD
Paroxetine—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	5.7e-05	0.000347	CcSEcCtD
Paroxetine—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	5.68e-05	0.000346	CcSEcCtD
Paroxetine—Asthenia—Salbutamol—chronic obstructive pulmonary disease	5.67e-05	0.000345	CcSEcCtD
Paroxetine—Sweating increased—Prednisone—chronic obstructive pulmonary disease	5.64e-05	0.000343	CcSEcCtD
Paroxetine—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	5.61e-05	0.000341	CcSEcCtD
Paroxetine—Pruritus—Salbutamol—chronic obstructive pulmonary disease	5.59e-05	0.00034	CcSEcCtD
Paroxetine—Erythema—Prednisolone—chronic obstructive pulmonary disease	5.56e-05	0.000338	CcSEcCtD
Paroxetine—Dizziness—Formoterol—chronic obstructive pulmonary disease	5.54e-05	0.000337	CcSEcCtD
Paroxetine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	5.54e-05	0.000337	CcSEcCtD
Paroxetine—Dizziness—Montelukast—chronic obstructive pulmonary disease	5.42e-05	0.00033	CcSEcCtD
Paroxetine—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	5.41e-05	0.000329	CcSEcCtD
Paroxetine—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	5.34e-05	0.000325	CcSEcCtD
Paroxetine—Vomiting—Formoterol—chronic obstructive pulmonary disease	5.32e-05	0.000324	CcSEcCtD
Paroxetine—Vomiting—Arformoterol—chronic obstructive pulmonary disease	5.32e-05	0.000324	CcSEcCtD
Paroxetine—Rash—Arformoterol—chronic obstructive pulmonary disease	5.28e-05	0.000321	CcSEcCtD
Paroxetine—Rash—Formoterol—chronic obstructive pulmonary disease	5.28e-05	0.000321	CcSEcCtD
Paroxetine—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	5.27e-05	0.000321	CcSEcCtD
Paroxetine—Dermatitis—Formoterol—chronic obstructive pulmonary disease	5.27e-05	0.000321	CcSEcCtD
Paroxetine—Weight increased—Prednisone—chronic obstructive pulmonary disease	5.27e-05	0.000321	CcSEcCtD
Paroxetine—Headache—Formoterol—chronic obstructive pulmonary disease	5.25e-05	0.000319	CcSEcCtD
Paroxetine—Headache—Arformoterol—chronic obstructive pulmonary disease	5.25e-05	0.000319	CcSEcCtD
Paroxetine—Weight decreased—Prednisone—chronic obstructive pulmonary disease	5.24e-05	0.000319	CcSEcCtD
Paroxetine—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	5.24e-05	0.000319	CcSEcCtD
Paroxetine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	5.23e-05	0.000318	CcSEcCtD
Paroxetine—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	5.23e-05	0.000318	CcSEcCtD
Paroxetine—Vomiting—Montelukast—chronic obstructive pulmonary disease	5.21e-05	0.000317	CcSEcCtD
Paroxetine—Rash—Montelukast—chronic obstructive pulmonary disease	5.17e-05	0.000315	CcSEcCtD
Paroxetine—Dermatitis—Montelukast—chronic obstructive pulmonary disease	5.17e-05	0.000314	CcSEcCtD
Paroxetine—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	5.15e-05	0.000314	CcSEcCtD
Paroxetine—Depression—Prednisone—chronic obstructive pulmonary disease	5.15e-05	0.000313	CcSEcCtD
Paroxetine—Headache—Montelukast—chronic obstructive pulmonary disease	5.14e-05	0.000313	CcSEcCtD
Paroxetine—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	5.09e-05	0.00031	CcSEcCtD
Paroxetine—Angioedema—Prednisolone—chronic obstructive pulmonary disease	5.08e-05	0.000309	CcSEcCtD
Paroxetine—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	5.06e-05	0.000308	CcSEcCtD
Paroxetine—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	5.06e-05	0.000308	CcSEcCtD
Paroxetine—Vomiting—Salbutamol—chronic obstructive pulmonary disease	5.03e-05	0.000306	CcSEcCtD
Paroxetine—Malaise—Prednisolone—chronic obstructive pulmonary disease	5.01e-05	0.000305	CcSEcCtD
Paroxetine—Vertigo—Prednisolone—chronic obstructive pulmonary disease	4.99e-05	0.000304	CcSEcCtD
Paroxetine—Rash—Salbutamol—chronic obstructive pulmonary disease	4.98e-05	0.000303	CcSEcCtD
Paroxetine—Syncope—Prednisolone—chronic obstructive pulmonary disease	4.98e-05	0.000303	CcSEcCtD
Paroxetine—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	4.98e-05	0.000303	CcSEcCtD
Paroxetine—Nausea—Arformoterol—chronic obstructive pulmonary disease	4.97e-05	0.000303	CcSEcCtD
Paroxetine—Nausea—Formoterol—chronic obstructive pulmonary disease	4.97e-05	0.000303	CcSEcCtD
Paroxetine—Headache—Salbutamol—chronic obstructive pulmonary disease	4.95e-05	0.000301	CcSEcCtD
Paroxetine—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	4.88e-05	0.000297	CcSEcCtD
Paroxetine—Nausea—Montelukast—chronic obstructive pulmonary disease	4.87e-05	0.000296	CcSEcCtD
Paroxetine—Convulsion—Prednisolone—chronic obstructive pulmonary disease	4.81e-05	0.000293	CcSEcCtD
Paroxetine—Hypertension—Prednisolone—chronic obstructive pulmonary disease	4.8e-05	0.000292	CcSEcCtD
Paroxetine—Bradycardia—Prednisone—chronic obstructive pulmonary disease	4.72e-05	0.000287	CcSEcCtD
Paroxetine—Nausea—Salbutamol—chronic obstructive pulmonary disease	4.7e-05	0.000286	CcSEcCtD
Paroxetine—Discomfort—Prednisolone—chronic obstructive pulmonary disease	4.67e-05	0.000284	CcSEcCtD
Paroxetine—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	4.66e-05	0.000284	CcSEcCtD
Paroxetine—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	4.64e-05	0.000282	CcSEcCtD
Paroxetine—Hallucination—Prednisone—chronic obstructive pulmonary disease	4.61e-05	0.000281	CcSEcCtD
Paroxetine—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	4.56e-05	0.000277	CcSEcCtD
Paroxetine—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	4.53e-05	0.000276	CcSEcCtD
Paroxetine—Oedema—Prednisolone—chronic obstructive pulmonary disease	4.53e-05	0.000276	CcSEcCtD
Paroxetine—Shock—Prednisolone—chronic obstructive pulmonary disease	4.46e-05	0.000271	CcSEcCtD
Paroxetine—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	4.43e-05	0.000269	CcSEcCtD
Paroxetine—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	4.38e-05	0.000267	CcSEcCtD
Paroxetine—Eye disorder—Prednisone—chronic obstructive pulmonary disease	4.33e-05	0.000264	CcSEcCtD
Paroxetine—Flushing—Prednisone—chronic obstructive pulmonary disease	4.3e-05	0.000262	CcSEcCtD
Paroxetine—Angiopathy—Prednisone—chronic obstructive pulmonary disease	4.21e-05	0.000256	CcSEcCtD
Paroxetine—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	4.19e-05	0.000255	CcSEcCtD
Paroxetine—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	4.14e-05	0.000252	CcSEcCtD
Paroxetine—Insomnia—Prednisolone—chronic obstructive pulmonary disease	4.1e-05	0.00025	CcSEcCtD
Paroxetine—Alopecia—Prednisone—chronic obstructive pulmonary disease	4.1e-05	0.000249	CcSEcCtD
Paroxetine—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	4.07e-05	0.000248	CcSEcCtD
Paroxetine—Mental disorder—Prednisone—chronic obstructive pulmonary disease	4.06e-05	0.000247	CcSEcCtD
Paroxetine—Malnutrition—Prednisone—chronic obstructive pulmonary disease	4.04e-05	0.000246	CcSEcCtD
Paroxetine—Erythema—Prednisone—chronic obstructive pulmonary disease	4.04e-05	0.000246	CcSEcCtD
Paroxetine—Pain—Prednisolone—chronic obstructive pulmonary disease	3.88e-05	0.000236	CcSEcCtD
Paroxetine—Vision blurred—Prednisone—chronic obstructive pulmonary disease	3.8e-05	0.000232	CcSEcCtD
Paroxetine—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	3.75e-05	0.000228	CcSEcCtD
Paroxetine—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	3.74e-05	0.000227	CcSEcCtD
Paroxetine—Anaemia—Prednisone—chronic obstructive pulmonary disease	3.73e-05	0.000227	CcSEcCtD
Paroxetine—Agitation—Prednisone—chronic obstructive pulmonary disease	3.71e-05	0.000226	CcSEcCtD
Paroxetine—Angioedema—Prednisone—chronic obstructive pulmonary disease	3.69e-05	0.000224	CcSEcCtD
Paroxetine—Malaise—Prednisone—chronic obstructive pulmonary disease	3.64e-05	0.000222	CcSEcCtD
Paroxetine—Vertigo—Prednisone—chronic obstructive pulmonary disease	3.63e-05	0.000221	CcSEcCtD
Paroxetine—Syncope—Prednisone—chronic obstructive pulmonary disease	3.62e-05	0.00022	CcSEcCtD
Paroxetine—Urticaria—Prednisolone—chronic obstructive pulmonary disease	3.6e-05	0.000219	CcSEcCtD
Paroxetine—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	3.55e-05	0.000216	CcSEcCtD
Paroxetine—Convulsion—Prednisone—chronic obstructive pulmonary disease	3.5e-05	0.000213	CcSEcCtD
Paroxetine—Hypertension—Prednisone—chronic obstructive pulmonary disease	3.49e-05	0.000212	CcSEcCtD
Paroxetine—Myalgia—Prednisone—chronic obstructive pulmonary disease	3.44e-05	0.000209	CcSEcCtD
Paroxetine—Arthralgia—Prednisone—chronic obstructive pulmonary disease	3.44e-05	0.000209	CcSEcCtD
Paroxetine—Anxiety—Prednisone—chronic obstructive pulmonary disease	3.43e-05	0.000208	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	3.41e-05	0.000208	CcSEcCtD
Paroxetine—Discomfort—Prednisone—chronic obstructive pulmonary disease	3.4e-05	0.000207	CcSEcCtD
Paroxetine—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	3.34e-05	0.000203	CcSEcCtD
Paroxetine—Oedema—Prednisone—chronic obstructive pulmonary disease	3.29e-05	0.0002	CcSEcCtD
Paroxetine—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	3.29e-05	0.0002	CcSEcCtD
Paroxetine—Infection—Prednisone—chronic obstructive pulmonary disease	3.27e-05	0.000199	CcSEcCtD
Paroxetine—Shock—Prednisone—chronic obstructive pulmonary disease	3.24e-05	0.000197	CcSEcCtD
Paroxetine—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	3.23e-05	0.000197	CcSEcCtD
Paroxetine—Tachycardia—Prednisone—chronic obstructive pulmonary disease	3.22e-05	0.000196	CcSEcCtD
Paroxetine—Skin disorder—Prednisone—chronic obstructive pulmonary disease	3.2e-05	0.000195	CcSEcCtD
Paroxetine—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	3.19e-05	0.000194	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	3e-05	0.000183	CcSEcCtD
Paroxetine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	3e-05	0.000182	CcSEcCtD
Paroxetine—Insomnia—Prednisone—chronic obstructive pulmonary disease	2.98e-05	0.000181	CcSEcCtD
Paroxetine—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	2.96e-05	0.00018	CcSEcCtD
Paroxetine—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	2.9e-05	0.000176	CcSEcCtD
Paroxetine—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	2.86e-05	0.000174	CcSEcCtD
Paroxetine—Rash—Prednisolone—chronic obstructive pulmonary disease	2.86e-05	0.000174	CcSEcCtD
Paroxetine—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	2.86e-05	0.000174	CcSEcCtD
Paroxetine—Fatigue—Prednisone—chronic obstructive pulmonary disease	2.84e-05	0.000173	CcSEcCtD
Paroxetine—Headache—Prednisolone—chronic obstructive pulmonary disease	2.84e-05	0.000173	CcSEcCtD
Paroxetine—Constipation—Prednisone—chronic obstructive pulmonary disease	2.82e-05	0.000171	CcSEcCtD
Paroxetine—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	2.72e-05	0.000165	CcSEcCtD
Paroxetine—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	2.69e-05	0.000164	CcSEcCtD
Paroxetine—Nausea—Prednisolone—chronic obstructive pulmonary disease	2.69e-05	0.000164	CcSEcCtD
Paroxetine—Urticaria—Prednisone—chronic obstructive pulmonary disease	2.62e-05	0.000159	CcSEcCtD
Paroxetine—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	2.6e-05	0.000158	CcSEcCtD
Paroxetine—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	2.6e-05	0.000158	CcSEcCtD
Paroxetine—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	2.43e-05	0.000148	CcSEcCtD
Paroxetine—Asthenia—Prednisone—chronic obstructive pulmonary disease	2.36e-05	0.000144	CcSEcCtD
Paroxetine—Pruritus—Prednisone—chronic obstructive pulmonary disease	2.33e-05	0.000142	CcSEcCtD
Paroxetine—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	2.25e-05	0.000137	CcSEcCtD
Paroxetine—Dizziness—Prednisone—chronic obstructive pulmonary disease	2.18e-05	0.000133	CcSEcCtD
Paroxetine—Vomiting—Prednisone—chronic obstructive pulmonary disease	2.09e-05	0.000127	CcSEcCtD
Paroxetine—Rash—Prednisone—chronic obstructive pulmonary disease	2.08e-05	0.000126	CcSEcCtD
Paroxetine—Dermatitis—Prednisone—chronic obstructive pulmonary disease	2.08e-05	0.000126	CcSEcCtD
Paroxetine—Headache—Prednisone—chronic obstructive pulmonary disease	2.06e-05	0.000126	CcSEcCtD
Paroxetine—Nausea—Prednisone—chronic obstructive pulmonary disease	1.96e-05	0.000119	CcSEcCtD
Paroxetine—CHRM3—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	1.54e-05	0.000373	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.53e-05	0.000371	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	1.53e-05	0.000369	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.51e-05	0.000365	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	1.5e-05	0.000363	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.47e-05	0.000356	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	1.47e-05	0.000355	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	1.46e-05	0.000353	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.45e-05	0.000352	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	1.45e-05	0.000352	CbGpPWpGaD
Paroxetine—SLC6A3—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.45e-05	0.00035	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.44e-05	0.000349	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.44e-05	0.000349	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	1.44e-05	0.000348	CbGpPWpGaD
Paroxetine—CHRM1—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	1.43e-05	0.000346	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.43e-05	0.000346	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	1.42e-05	0.000342	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	1.4e-05	0.000339	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.4e-05	0.000338	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.38e-05	0.000333	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.35e-05	0.000327	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.33e-05	0.000322	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.32e-05	0.00032	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.32e-05	0.000319	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.32e-05	0.000318	CbGpPWpGaD
Paroxetine—CHRM1—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	1.31e-05	0.000317	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.31e-05	0.000317	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.31e-05	0.000316	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.3e-05	0.000316	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.3e-05	0.000315	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.3e-05	0.000314	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.29e-05	0.000313	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.29e-05	0.000313	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.29e-05	0.000311	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—GCLC—chronic obstructive pulmonary disease	1.28e-05	0.000309	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.28e-05	0.000309	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.26e-05	0.000304	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.25e-05	0.000303	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.25e-05	0.000303	CbGpPWpGaD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	1.25e-05	0.000302	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	1.25e-05	0.000302	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.25e-05	0.000302	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.25e-05	0.000301	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.24e-05	0.000301	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.24e-05	0.0003	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	1.24e-05	0.0003	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	1.24e-05	0.000299	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.23e-05	0.000298	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.23e-05	0.000298	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.22e-05	0.000295	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.2e-05	0.000291	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	1.2e-05	0.00029	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.19e-05	0.000288	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.18e-05	0.000286	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.18e-05	0.000285	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.17e-05	0.000283	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CTGF—chronic obstructive pulmonary disease	1.17e-05	0.000282	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.16e-05	0.000281	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.16e-05	0.000281	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	1.15e-05	0.000277	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.14e-05	0.000276	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.14e-05	0.000275	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.13e-05	0.000272	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	1.12e-05	0.000272	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.11e-05	0.000269	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.11e-05	0.000269	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.1e-05	0.000267	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.1e-05	0.000266	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.07e-05	0.00026	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	1.07e-05	0.000259	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.04e-05	0.000253	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.04e-05	0.000251	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.04e-05	0.000251	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.03e-05	0.00025	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.03e-05	0.00025	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.02e-05	0.000247	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CTGF—chronic obstructive pulmonary disease	1e-05	0.000243	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1e-05	0.000242	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	9.93e-06	0.00024	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	9.91e-06	0.00024	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	9.48e-06	0.000229	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	9.43e-06	0.000228	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9.42e-06	0.000228	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.42e-06	0.000228	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GCLC—chronic obstructive pulmonary disease	9.31e-06	0.000225	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.24e-06	0.000224	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	9.16e-06	0.000222	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	9.12e-06	0.000221	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	9.09e-06	0.00022	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	9.09e-06	0.00022	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	9.08e-06	0.00022	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	9.07e-06	0.000219	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9.02e-06	0.000218	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	9e-06	0.000218	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.96e-06	0.000217	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	8.92e-06	0.000216	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.84e-06	0.000214	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	8.68e-06	0.00021	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	8.68e-06	0.00021	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—KL—chronic obstructive pulmonary disease	8.52e-06	0.000206	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CTGF—chronic obstructive pulmonary disease	8.49e-06	0.000205	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—KL—chronic obstructive pulmonary disease	8.47e-06	0.000205	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—KL—chronic obstructive pulmonary disease	8.45e-06	0.000204	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.43e-06	0.000204	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—KL—chronic obstructive pulmonary disease	8.37e-06	0.000202	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.24e-06	0.000199	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.2e-06	0.000198	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	8.11e-06	0.000196	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.07e-06	0.000195	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	7.86e-06	0.00019	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.83e-06	0.000189	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	7.82e-06	0.000189	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.81e-06	0.000189	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	7.8e-06	0.000189	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.73e-06	0.000187	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	7.72e-06	0.000187	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.71e-06	0.000187	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.66e-06	0.000185	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	7.64e-06	0.000185	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.6e-06	0.000184	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	7.58e-06	0.000183	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	7.49e-06	0.000181	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	7.4e-06	0.000179	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	7.19e-06	0.000174	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.08e-06	0.000171	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	7.08e-06	0.000171	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	7.06e-06	0.000171	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	7.04e-06	0.00017	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	7.03e-06	0.00017	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	7.02e-06	0.00017	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	6.99e-06	0.000169	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	6.97e-06	0.000169	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	6.97e-06	0.000169	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	6.95e-06	0.000168	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	6.93e-06	0.000168	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	6.91e-06	0.000167	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	6.9e-06	0.000167	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	6.85e-06	0.000166	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.82e-06	0.000165	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.72e-06	0.000162	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	6.64e-06	0.000161	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.61e-06	0.00016	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.53e-06	0.000158	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.44e-06	0.000156	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	6.43e-06	0.000156	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.42e-06	0.000155	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	6.39e-06	0.000155	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	6.39e-06	0.000155	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	6.37e-06	0.000154	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.37e-06	0.000154	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	6.35e-06	0.000154	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.33e-06	0.000153	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	6.33e-06	0.000153	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.32e-06	0.000153	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	6.31e-06	0.000153	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	6.27e-06	0.000152	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	6.11e-06	0.000148	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	6.09e-06	0.000147	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.05e-06	0.000146	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	6.04e-06	0.000146	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GSTM1—chronic obstructive pulmonary disease	6e-06	0.000145	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	5.71e-06	0.000138	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.69e-06	0.000138	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.69e-06	0.000138	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	5.68e-06	0.000138	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—LEP—chronic obstructive pulmonary disease	5.67e-06	0.000137	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	5.61e-06	0.000136	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.61e-06	0.000136	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.6e-06	0.000136	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.36e-06	0.00013	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.36e-06	0.00013	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.33e-06	0.000129	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.31e-06	0.000129	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—ALB—chronic obstructive pulmonary disease	5.31e-06	0.000128	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.28e-06	0.000128	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.24e-06	0.000127	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.23e-06	0.000126	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.1e-06	0.000123	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—NOS3—chronic obstructive pulmonary disease	5.08e-06	0.000123	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.07e-06	0.000123	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.95e-06	0.00012	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.92e-06	0.000119	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.88e-06	0.000118	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.85e-06	0.000117	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.7e-06	0.000114	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.67e-06	0.000113	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.67e-06	0.000113	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.66e-06	0.000113	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.63e-06	0.000112	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.61e-06	0.000112	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—ALB—chronic obstructive pulmonary disease	4.57e-06	0.00011	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.55e-06	0.00011	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.48e-06	0.000108	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.46e-06	0.000108	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.45e-06	0.000108	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.4e-06	0.000107	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—NOS3—chronic obstructive pulmonary disease	4.37e-06	0.000106	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.36e-06	0.000105	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.28e-06	0.000104	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.26e-06	0.000103	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.24e-06	0.000103	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.2e-06	0.000102	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.18e-06	0.000101	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.09e-06	9.91e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4e-06	9.68e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.92e-06	9.49e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ALB—chronic obstructive pulmonary disease	3.87e-06	9.35e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.8e-06	9.19e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.78e-06	9.14e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.77e-06	9.11e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.73e-06	9.02e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—NOS3—chronic obstructive pulmonary disease	3.7e-06	8.94e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.61e-06	8.74e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.59e-06	8.69e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.58e-06	8.66e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.55e-06	8.58e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.44e-06	8.32e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.43e-06	8.31e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.42e-06	8.27e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.41e-06	8.24e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.37e-06	8.16e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	3.37e-06	8.15e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.29e-06	7.96e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	3.22e-06	7.79e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	3.17e-06	7.68e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.15e-06	7.61e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	3.15e-06	7.61e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.08e-06	7.46e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.07e-06	7.42e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.06e-06	7.4e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	3.04e-06	7.34e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.03e-06	7.33e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.01e-06	7.29e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	3.01e-06	7.28e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.83e-06	6.85e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.82e-06	6.81e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.81e-06	6.79e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.78e-06	6.72e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.78e-06	6.72e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.76e-06	6.68e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.75e-06	6.66e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.73e-06	6.59e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.33e-06	5.64e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.32e-06	5.61e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.31e-06	5.59e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.29e-06	5.54e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.13e-06	5.16e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.12e-06	5.13e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.11e-06	5.12e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.09e-06	5.07e-05	CbGpPWpGaD
